Martin Stuschke
Overview
Explore the profile of Martin Stuschke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
230
Citations
3951
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Schulte C, Gauler T, Pottgen C, Friedel G, Kopp H, Fischer B, et al.
Int J Cancer
. 2024 Aug;
156(1):154-163.
PMID: 39198970
Over 40% stage-III non-small-cell lung cancer (NSCLC) patients (pts) experience 5-year survival following multimodality treatment. Nevertheless, little is known about relevant late toxicities and quality-of-life (QoL) in the further long-term...
12.
Lin X, Soni A, Hessenow R, Sun Y, Mladenov E, Guberina M, et al.
Radiother Oncol
. 2024 Aug;
200:110475.
PMID: 39147034
Background And Purpose: The PARP inhibitor (PARPi), Talazoparib (BMN673), effectively and specifically radiosensitizes cancer cells. Radiosensitization is mediated by a shift in the repair of ionizing radiation (IR)-induced DNA double-strand...
13.
Dobersalske C, Rauschenbach L, Hua Y, Berliner C, Steinbach A, Gruneboom A, et al.
Nat Med
. 2024 Jul;
30(10):2947-2956.
PMID: 39085419
The ecosystem of brain tumors is considered immunosuppressed, but our current knowledge may be incomplete. Here we analyzed clinical cell and tissue specimens derived from patients presenting with glioblastoma or...
14.
Kessler L, Schwaning F, Metzenmacher M, Pabst K, Siveke J, Trajkovic-Arsic M, et al.
J Nucl Med
. 2024 Jul;
65(8):1188-1193.
PMID: 38960716
The fibroblast activation protein (FAP) is highly expressed in tumor and stromal cells of mesothelioma and thus is an interesting imaging and therapeutic target. Previous data on PET imaging with...
15.
Oster C, Kessler L, Blau T, Keyvani K, Pabst K, Fendler W, et al.
J Nucl Med
. 2024 Jul;
65(8):1217-1223.
PMID: 38960714
Despite their unique histologic features, gliosarcomas belong to the group of glioblastomas and are treated according to the same standards. Fibroblast activation protein (FAP) is a component of a tumor-specific...
16.
Richlitzki C, Wiesweg M, Metzenmacher M, Guberina N, Pottgen C, Hautzel H, et al.
Sci Rep
. 2024 Jun;
14(1):13765.
PMID: 38877146
To evaluate the prognostic value of biomarkers from peripheral blood obtained as routine laboratory assessment for overall survival in a cohort of stage III non-small cell lung cancer (NSCLC) patients...
17.
Jabbarli L, Biewald E, Guberina M, Rating P, Fiorentzis M, Fluhs D, et al.
Eur J Ophthalmol
. 2024 May;
35(1):357-366.
PMID: 38807558
Purpose: Radiation-induced scleral necrosis (RISN) is a less frequent complication of brachytherapy for uveal melanoma, and may require surgical treatment in selected cases. We aimed to identify the prognostic factors...
18.
Watanabe M, Fendler W, Grafe H, Hirmas N, Hamacher R, Lanzafame H, et al.
J Nucl Med
. 2024 May;
65(7):1027-1034.
PMID: 38782454
Tumoral fibroblast activation protein expression is associated with proliferation and angiogenesis and can be visualized by PET/CT. We examined the prognostic value of [Ga]Ga-fibroblast activation protein inhibitor (FAPI) (Ga-FAPI)-46 PET/CT...
19.
Nikitas J, Lam E, Booker K, Fendler W, Eiber M, Hadaschik B, et al.
J Nucl Med
. 2024 Apr;
65(7):1076-1079.
PMID: 38664019
This multicenter randomized phase III trial (NCT04457245) evaluated the effect of performing prostate-specific membrane antigen (PSMA) PET/CT before definitive radiotherapy. Men with unfavorable intermediate- or high-risk prostate cancer were randomized...
20.
Ebert M, Fischbach W, Hollerbach S, Hoppner J, Lorenz D, Stahl M, et al.
Z Gastroenterol
. 2024 Apr;
62(4):535-642.
PMID: 38599580
No abstract available.